688222 Stock Overview
Operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for 688222 from our risk checks.
HitGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.04 |
| 52 Week High | CN¥19.35 |
| 52 Week Low | CN¥8.85 |
| Beta | 0.16 |
| 1 Month Change | 12.90% |
| 3 Month Change | 19.52% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688222 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -2.5% | -2.9% | -1.5% |
| 1Y | n/a | -32.5% | -11.3% |
Return vs Industry: Insufficient data to determine how 688222 performed against the CN Life Sciences industry.
Return vs Market: Insufficient data to determine how 688222 performed against the CN Market.
Price Volatility
| 688222 volatility | |
|---|---|
| 688222 Average Weekly Movement | 8.7% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688222 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688222's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 464 | Li Jin | www.hitgen.com |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGT01 and HGT02, an tumor immunology for cancer.
HitGen Inc. Fundamentals Summary
| 688222 fundamental statistics | |
|---|---|
| Market cap | CN¥5.21b |
| Earnings (TTM) | CN¥67.28m |
| Revenue (TTM) | CN¥409.47m |
77.7x
P/E Ratio12.8x
P/S RatioIs 688222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688222 income statement (TTM) | |
|---|---|
| Revenue | CN¥409.47m |
| Cost of Revenue | CN¥5.89m |
| Gross Profit | CN¥403.58m |
| Other Expenses | CN¥336.30m |
| Earnings | CN¥67.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 98.56% |
| Net Profit Margin | 16.43% |
| Debt/Equity Ratio | 14.9% |
How did 688222 perform over the long term?
See historical performance and comparison